Cellectar Biosciences- Cellectar Biosciences open label, multicenter, Phase II study of CLR 131 in patients with relapsed or refractory select B-cell malignancies and expansion cohort in patients with Waldenstrom Macroglobulinemia clinical trial.
Genmab- A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma.
EGOG-EA8185- Phase II Study of Bladder-Sparing Chemoradiation with Durvalumab in Clinical Stage III
Alliance A011801- The compassher2 trials (comprehensive use of pathologic response assessment to optimize therapy in her2-positive breast cancer): A double-blinded, phase III randomized trial of t-dm1 and placebo compared with t-dm1 and tucatinib.
Merck MK3475-B49– a randomized, double-blind, placebo-controlled, Phase III study of Pembrolizumab plus chemotherapy versus Placebo plus chemotherapy for the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2- negative metastatic breast cancer.
SWOG S1706- A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer.
SWOG S2007– A Phase II Trial for patients with HER2-Negative Breast Cancer and Brain Metastases.
TransThera– A Phase 2, Open Label, Multicenter study to evaluate the efficacy and safety of TT-00420 tablet in adult patients with advanced Cholangiocarcinoma.
Chronic Lymphocytic Leukemia
Genentech — A prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of a combined regimen of Obinutuzumab and Venetoclax versus Fludarabine, Cyclophosphamide and Rituximab (FCR)/Bendamustine and Rituximab (BR) in for patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without Del (17P) or TP53 mutation.
Natera — BESPOKE CRC study for patients who have been diagnosed with State II or III CRC and will be tested with Signatera.
Xilis- Microorgano Sphere (MOS) Drug screen to lead care (MODEL) Precision oncology pilot trial in colorectal cancer.
Chiesi Ready 1 CUSA-081-HEM-01 — A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs).
Epizyme/Parexel — A Phase 1b/3 Double-Blind, Randomized, Placebo-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat in Combination with Lenalidomide Plus Rituximab vs Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma.
ECOG EA2197- Phase II/III trial to compare neoadjuvant Gemcitabine/Cisplatin and adjuvant Gemcitabine/Cisplatin in Stage T2 vs T3 incidental Gallbladder Cancer
Head and Neck
PDS Biotech/iQVIA — A Phase II, Open-Label, Multi-Center Study of PDS0101 (ImmunoMAPK-RDOTAP/HPV-16 E6 & E7 peptides) and Pembrolizumab (KEYTRUDA) Combination Immunotherapy as a First Line Treatment in Patients with Recurrent and/or Metastatic Head and Neck Cancer and High-risk Human Papillomavirus-16 (HPV16) Infection.
NRG HN005- a randomized, Phase II/III trial of de-intensified radiation therapy for patients with early stage, P16 positive, non-smoking associated oropharyngeal cancer.
BeiGene — A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with relapsed or refractory classical Hodgkin Lymphoma.
Merck C11- Phase 2 study of pembrolizumab and chemotherapy in patients with newly diagnosed classical Hodgkin Lymphoma.
Trillium TTI-622-01 — A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients with Advanced Relapsed or Refractory Lymphoma or Myeloma.
Seattle Genetics SGN35-032 — Dual cohort, open label, Phase 2 study of BV and CHP (A+CHP) in the frontline treatment of patients with PTCL with less than 10% CD30 expression.
ONO Pharma– An open-label phase II trial to investigate the efficacy and safety for patients with relapsed or refractory Primary Central Nervous System Lymphoma
Amgen Herpetic Infection 20130193 — A post-marketing prospective cohort study of Melanoma patients treated with Imlygic (Talimogene Laherparepvec) in clinical practice to characterize the risk of Herpetic infection among patients, close contacts, and health care providers, and long-term safety in treated patients.
BMS- A Phase 3, Open label, randomized, non-inferiority pharmacokinetic study of Nivolumab administered subcutaneously by autoinjector versus IV in patients with Stage IIIA/B/C/D or Stage IV adjuvant melanoma following complete resection.
Pfizer C4221016 — A phase 3, randomized, double-blind study of Encorafenib and Binimetinib plus Pembrolizumab versus placebo plus Pembrolizumab in previously untreated BRAF V600E/K mutation-positive participants with unresectable or metastatic melanoma.
Regeneron- A Phase 3 trial of Fianlimab (REGN-3767, Anti-LAG 3) + Cemiplimab vs. Pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.
Natera Bespoke- Immunotherapy monitoring clinical trial
ECOG EA6174- a Phase III study of adjuvant Pembrolizumab vs Observation in surgically treated Merkel Cell.
Non-Small Cell Lung Cancer
Altor Bioscience Quilt 2.023 — A study of ALT-803, a fusion protection activator of natural killer and T-cells, in combination with Pembrolizumab vs Pembrolizumab alone as first-line treatment for patients with metastatic non-small cell lung cancer.
Merck MK3475-867 — A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA NSCLC (KEYNOTE-867).
Mersana/GOG3048 — Phase 1b, first in human, dose escalation and expansion study of XMT-1536 in patients with solid tumors likely to express NaPi2b.
Merck MK3475-A86- Phase III study of Pembrolizumab SC plus chemotherapy versus Pembrolizumab IV plus chemotherapy in 1L metastatic squamous or non- squamous NSCLC.
Iovance- A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer.
Alliance A151216- adjuvant lung cancer enrichment marker identification and sequencing trial
Alliance A081801– integration of immunotherapy into adjuvant therapy for resected non small cell lung cancer
ECOG EA5163/S1709- a randomized, Phase III study of first line immunotherapy alone or in combination with chemotherapy in induction/maintenance or post progression in advanced non-squamous non-small cell lung cancer with immunobiomarker signature-driven analysis
ECOG E4512– a component of the Alchemist trial-a randomized Phase III trial for surgically resected early stage non- small cell lung cancer: Crizotinib versus observation for patients with tumors harboring the anaplastic lymphoma kinase (ALK) Fusion protein
Aravive GOG-3059- Phase III, randomized, double-blind, placebo/Paclitaxel-controlled study of AVB-S6-500 in combination with Paclitaxel in patients with platinum resistant recurrent ovarian cancer.
ECOG EA2185- a study comparing the clinical impact of pancreatic cyst surveillance programs
Alliance A021806- a Phase 3 trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer.
XBiotech- A phase I/II , double-blind, placebo-controlled trial examining XB2001 (anti-IL-1⍺ True Human antibody) in combination with ONIVYDE + 5-FU/LV (+folinic acid) in advanced pancreatic cancer.
Lilly CYCLONE 3- a Phase 3, global, multicenter study to evaluate Abemaciclib in combination with abiraterone and prednisone for the treatment of patients with high-risk metastatic hormone-sensitive prostate cancer.
MK-6482-012 — An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as first line treatment in Participants with Advanced ccRCC.
Alliance A031704– This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body.
Small Cell Lung Cancer
Merck MK7339-013 — A phase 3 study of Pembrolizumab in combination with concurrent chemoradiation therapy followed by Pembrolizumab with or without Olaparib, compared to concurrent chemoradiation therapy followed by placebo in participants with newly diagnosed treatment naïve limited-stage small cell lung cancer.
Cutaneous Squamous Cell Carcinoma
Regeneron Case — A prospective survivorship cohort study of adult patients with cutaneous squamous cell carcinoma undergoing treatment with Cemiplimab.
Castle Biosciences CBI-2019-cSCC-PVS-001 — Prospective Validation of a Gene Expression Assay to Predict the Risk of Recurrence Disease in Cutaneous Squamous Cell Carcinoma.
Alliance A091802– a Phase II, randomized trial of Avelumab plus Cetuximab vs. Avelumab alone in advance cutaneous squamous cell.
Alliance A032001— a Phase III randomized trial of maintenance Cabozantinib and Avelumab vs maintenance Avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer.
Immunomedics/PRA — A randomized open-label phase III study of Sacituzumab Govitecan versus treatment of physician’s choice in subjects with metastatic or locally advanced unresectable urothelial cancer.
Seattle Genetics RC48G001- A Phase 2 Mulit-cohort, open-label, multi-center clinical study evaluating the efficacy and safety of Disitamab Vedotin (RC48-ADC) in subjects with HER-2 expressing locally advanced unresenctable or metastatic urothelial carcinoma.